KalVista Pharmaceuticals Reports $49 Million Full-Year 2025 Revenue for EKTERLY Launch

Reuters

Jan 09

KalVista Pharmaceuticals Reports $49 Million Full-Year 2025 Revenue for EKTERLY Launch

KalVista Pharmaceuticals Inc. reported preliminary unaudited global net product revenue for EKTERLY® (sebetralstat) of approximately $35 million for the fourth quarter and $49 million for the full year 2025. The company initiated the US commercial launch of EKTERLY on July 7, 2025, and recorded 1,318 patient start forms with 580 unique prescribers in the US through December 31, 2025. In the fourth quarter of 2025, prescription refills became the primary driver of revenue, surpassing initial prescriptions. KalVista also expanded internationally, noting strong adoption in Germany and announcing an exclusive partnership with Multicare Pharmaceuticals, LLC to commercialize sebetralstat in Brazil, Argentina, Colombia, and Mexico. The company indicated plans to file a new drug application for pediatric patients aged 2-11 years in the third quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalvista Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260108509630) on January 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2602186873"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602186873\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602186873?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 05:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602186873","market":"fut","top_or_hot":-1,"title":"KalVista Pharmaceuticals Reports $49 Million Full-Year 2025 Revenue for EKTERLY Launch","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      KalVista Pharmaceuticals Reports $49 Million Full-Year 2025 Revenue for EKTERLY Launch\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        KalVista Pharmaceuticals Inc. reported preliminary unaudited global net product revenue for EKTERLY® (sebetralstat) of approximately $35 million for the fourth quarter and $49 million for the full year 2025. The company initiated the US commercial launch of EKTERLY on July 7, 2025, and recorded 1,318 patient start forms with 580 unique prescribers in the US through December 31, 2025. In the fourth quarter of 2025, prescription refills became the primary driver of revenue, surpassing initial prescriptions. KalVista also expanded internationally, noting strong adoption in Germany and announcing an exclusive partnership with Multicare Pharmaceuticals, LLC to commercialize sebetralstat in Brazil, Argentina, Colombia, and Mexico. The company indicated plans to file a new drug application for pediatric patients aged 2-11 years in the third quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/KALV\">Kalvista Pharmaceuticals Inc</a>. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260108509630) on January 08, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>KalVista Pharmaceuticals Reports $49 Million Full-Year 2025 Revenue for EKTERLY Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKalVista Pharmaceuticals Reports $49 Million Full-Year 2025 Revenue for EKTERLY Launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-09 05:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      KalVista Pharmaceuticals Reports $49 Million Full-Year 2025 Revenue for EKTERLY Launch\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        KalVista Pharmaceuticals Inc. reported preliminary unaudited global net product revenue for EKTERLY® (sebetralstat) of approximately $35 million for the fourth quarter and $49 million for the full year 2025. The company initiated the US commercial launch of EKTERLY on July 7, 2025, and recorded 1,318 patient start forms with 580 unique prescribers in the US through December 31, 2025. In the fourth quarter of 2025, prescription refills became the primary driver of revenue, surpassing initial prescriptions. KalVista also expanded internationally, noting strong adoption in Germany and announcing an exclusive partnership with Multicare Pharmaceuticals, LLC to commercialize sebetralstat in Brazil, Argentina, Colombia, and Mexico. The company indicated plans to file a new drug application for pediatric patients aged 2-11 years in the third quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/KALV\">Kalvista Pharmaceuticals Inc</a>. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260108509630) on January 08, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KALV","symbol_name":"Kalvista Pharmaceuticals Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL7Q03Fk:1","article_id":"2602186873","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602186873","pubTimestamp":1767906404,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"KalVista Pharmaceuticals Inc. reported preliminary unaudited global net product revenue for EKTERLY  of approximately $35 million for the fourth quarter and $49 million for the full year 2025. The company initiated the US commercial launch of EKTERLY on July 7, 2025, and recorded 1,318 patient start forms with 580 unique prescribers in the US through December 31, 2025. In the fourth quarter of 2025, prescription refills became the primary driver of revenue, surpassing initial prescriptions. KalVista also expanded internationally, noting strong adoption in Germany and announcing an exclusive partnership with Multicare Pharmaceuticals, LLC to commercialize sebetralstat in Brazil, Argentina, Colombia, and Mexico. The company indicated plans to file a new drug application for pediatric patients aged 2-11 years in the third quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and time","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KALV":"Kalvista Pharmaceuticals Inc","BK4139":"生物科技"},"translate_title":"KalVista Pharmaceuticals报告EKTERLY上市2025年全年收入为4900万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KALV":0.9},"content_text":"KalVista Pharmaceuticals Reports $49 Million Full-Year 2025 Revenue for EKTERLY Launch\n    \n\n        KalVista Pharmaceuticals Inc. reported preliminary unaudited global net product revenue for EKTERLY® (sebetralstat) of approximately $35 million for the fourth quarter and $49 million for the full year 2025. The company initiated the US commercial launch of EKTERLY on July 7, 2025, and recorded 1,318 patient start forms with 580 unique prescribers in the US through December 31, 2025. In the fourth quarter of 2025, prescription refills became the primary driver of revenue, surpassing initial prescriptions. KalVista also expanded internationally, noting strong adoption in Germany and announcing an exclusive partnership with Multicare Pharmaceuticals, LLC to commercialize sebetralstat in Brazil, Argentina, Colombia, and Mexico. The company indicated plans to file a new drug application for pediatric patients aged 2-11 years in the third quarter of 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalvista Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260108509630) on January 08, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}